Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT04292119
Lorlatinib Combinations in Lung Cancer
- NCT04292119 ↗
- Unknown
- Massachusetts General Hospital
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT04292119 (anaplastic lymphoma kinase-rearranged lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04292119 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase IB/II Study of Lorlatinib Combinations in Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
- Phase
- Phase 1/Phase 2
- Status
- Unknown
- Conditions
- Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement; Relapsed Cancer; MET Amplification; Resistant Cancer; NSCLC
- Interventions
- Lorlatinib; Crizotinib; Binimetinib; TNO155
- Arms
- Lorlatinib and Crizotinib · Experimental
- Lorlatinib and Binimetinib · Experimental
- Lorlatinib and TNO155 · Experimental
- Enrollment
- 96 (estimated)
- Primary outcomes
- Maximum tolerated dose as assessed by CTCAE v5.0. Phase I.
- The objective response rate, including partial and complete responses, as evaluated by RECIST v1.1. Phase II
- Sponsor
- Massachusetts General Hospital with Array BioPharma, Pfizer
- Start
- May 1, 2020
- Primary completion
- Dec 1, 2022 (estimated)
- Results posted
- No
- Registry record
- NCT04292119 · updated Mar 10, 2021